Browse recruiting and upcoming clinical trials for cold agglutinin disease.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults 18–75 with autoimmune hemolytic anemia (warm, mixed, Evans syndrome, or cold/CAD) who have failed at least three prior lines of therapy.
What is being studied AITests safety, tolerability, and dose of Inaticabtagene autoleucel CAR‑T in autoimmune hemolytic anemia.
Who can join AIAdults (≥18) with warm or cold autoimmune hemolytic anemia (primary or certain secondary autoimmune causes) who are refractory or relapsed after steroids.
What is being studied AITests iptacopan as a treatment for refractory or relapsed autoimmune hemolytic anemia.
Who can join AIPeople diagnosed with autoimmune hemolytic anemia (warm, cold, or mixed) with hemoglobin <100 g/L treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2001.
What is being studied AICollects clinical, treatment, outcome, and cost data on people diagnosed with autoimmune hemolytic anemia.